Amgen Inc. (AMGN) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Amgen financial statements at a glance

Amgen reported revenue of $36.75 billion for fiscal year 2025 (ended December 31, 2025), up 10.0% from fiscal year 2024. Net income was $7.71 billion, a net margin of 21.0%, and diluted earnings per share were $14.23.

At the end of fiscal year 2025 it had total assets of $90.59 billion, total liabilities of $81.93 billion and shareholders' equity of $8.66 billion, with cash and short-term investments of $9.13 billion and total debt of $54.60 billion.

Its operations brought in $9.96 billion of cash; capital spending was $1.86 billion, leaving free cash flow of $8.10 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

AMGN logo

Amgen Inc.

AMGNUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
36.75B
Prev Year: 33.42B
YoY: +10.0%
Operating Revenue
35.15B
Prev Year: 32.03B
YoY: +9.7%
Tax Rate for Calcs
0.141
Prev Year: 0
Total Unusual Items Excluding Goodwill
-
Total Operating Income as Reported
9.08B
Prev Year: 7.26B
YoY: +25.1%
Other Operating Expenses
1.31B
Prev Year: 248.00M
YoY: +429.0%
Cost of Revenue
12.04B
Prev Year: 12.86B
YoY: -6.4%
Gross Profit
24.71B
Prev Year: 20.57B
YoY: +20.2%
Operating Expense
15.63B
Prev Year: 13.31B
YoY: +17.5%
Selling General and Administrative
7.05B
Prev Year: 7.10B
YoY: -0.6%
Research and Development
7.27B
Prev Year: 5.96B
YoY: +21.9%
Operating Income
9.08B
Prev Year: 7.26B
YoY: +25.1%
Net Non Operating Interest Income Expense
-2.75B
Prev Year: -3.15B
YoY: +12.7%
Non-operating Interest Expense
2.75B
Prev Year: 3.15B
YoY: -12.7%
Non-operating Interest Income
-
Other Income Expense
2.65B
Prev Year: 506.00M
YoY: +423.9%
Other Non-operating Income (expense)
2.65B
Prev Year: 506.00M
YoY: +423.9%
Special Income Charges
-
Pre-tax Income
8.98B
Prev Year: 4.61B
YoY: +94.7%
Provision for Income Taxes
1.26B
Prev Year: 519.00M
YoY: +143.7%
Net Income Common Stockholders
7.71B
Prev Year: 4.09B
YoY: +88.5%
Net Income
7.71B
Prev Year: 4.09B
YoY: +88.5%
Net Income Including Non-Controlling Interests
7.71B
Prev Year: 4.09B
YoY: +88.5%
Net Income from Continuing Operations
7.71B
Prev Year: 4.09B
YoY: +88.5%
Diluted NI Available to Com Stockholders
7.71B
Prev Year: 4.09B
YoY: +88.5%
Basic EPS
14.33
Prev Year: 7.62
YoY: +88.1%
Diluted EPS
14.23
Prev Year: 7.56
YoY: +88.2%
Weighted Average Shares (basic)
538.00M
Prev Year: 537.00M
YoY: +0.2%
Weighted Average Shares (diluted)
542.00M
Prev Year: 541.00M
YoY: +0.2%
Total Expenses
27.67B
Prev Year: 26.17B
YoY: +5.8%
Net Income from Continuing and Discontinued Operation
7.71B
Prev Year: 4.09B
YoY: +88.5%
Normalized Income
7.71B
Prev Year: 4.09B
YoY: +88.5%
Interest Expense
2.75B
Prev Year: 3.15B
YoY: -12.7%
Net Interest Income
-2.75B
Prev Year: -3.15B
YoY: +12.7%
Interest Income
-
EBIT
11.73B
Prev Year: 7.76B
YoY: +51.1%
EBITDA
16.90B
Prev Year: 13.36B
YoY: +26.5%
Reconciled Cost of Revenue
12.04B
Prev Year: 12.86B
YoY: -6.4%
Reconciled Depreciation
5.17B
Prev Year: 5.59B
YoY: -7.6%
Net Income from Continuing Operation Net Minority Interest
7.71B
Prev Year: 4.09B
YoY: +88.5%
Normalized EBITDA
16.90B
Prev Year: 13.36B
YoY: +26.5%
Values in USD

Amgen key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$36.8B$33.4B$28.2B$26.3B$26.0B
Gross profit$24.7B$20.6B$19.7B$19.9B$19.5B
Operating income$9.1B$7.3B$7.9B$9.6B$9.1B
Net income$7.7B$4.1B$6.7B$6.6B$5.9B
Diluted EPS$14.23$7.56$12.49$12.11$10.28
Total assets$90.6B$91.8B$97.2B$65.1B$61.2B
Total liabilities$81.9B$86.0B$90.9B$61.5B$54.5B
Shareholders' equity$8.7B$5.9B$6.2B$3.7B$6.7B
Cash and short-term investments$9.1B$12.0B$10.9B$9.3B$8.0B
Total debt$54.6B$60.1B$64.6B$38.9B$33.3B
Operating cash flow$10.0B$11.5B$8.5B$9.7B$9.3B
Capital spending$1.9B$1.1B$1.1B$936.0M$880.0M
Free cash flow$8.1B$10.4B$7.4B$8.8B$8.4B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Amgen's revenue in fiscal year 2025?

$36.75 billion, up 10.0% from $33.42 billion in fiscal year 2024.

How much profit does Amgen make?

Amgen reported net income of $7.71 billion for fiscal year 2025 (21.0% of revenue); operating income was $9.08 billion.

How much cash and debt does Amgen have?

At the end of fiscal year 2025: cash and short-term investments of $9.13 billion and total debt of $54.60 billion.

What is Amgen's free cash flow?

$8.10 billion in fiscal year 2025 (operating cash flow of $9.96 billion minus capital spending of $1.86 billion).

MoreAmgen stock overviewAmgen executive teamAmgen shareholdersAmgen revenue by segment
RelatedBiological Product (except Diagnostic) Manufacturing industryManufacturing sectorAbbVie financialsNovartis financialsAstraZeneca financialsPfizer financialsSanofi financialsGSK financials
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube